« Return to News | CROs/Service Providers

INC Research, SAS collaborate to improve clinical development

Wednesday, November 16, 2011 01:59 PM

INC Research and SAS are working together to improve clinical development risk management and achieve targeted product profiles through analytics. Collaborating with SAS, INC Research will offer biopharmaceutical customers an integrated suite of tools to increase decision-making speed, efficiency and flexibility. The ultimate goal is to improve a customer’s ability to manage risk, control investment and maximize ROI in clinical development.

“In an environment of growing trial complexity and shrinking R&D budgets, our biopharmaceutical customers demand innovative solutions and enhanced efficiencies in drug development,” said James Ogle, INC Research chief executive officer. “By joining forces with SAS and its advanced analytics platform, INC Research can help customers better predict commercially successful outcomes earlier in the process to maximize development efforts.”

SAS’ advanced analytics platform will boost INC Research’s ability to optimize clinical trial designs and proactively manage operations. By gaining access to SAS software through a hosted delivery model, INC Research customers will achieve more rapid and informed decisions, faster time to market, and improved cash flow.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.